Last reviewed · How we verify

GH treatment (Genotropin) — Competitive Intelligence Brief

GH treatment (Genotropin) (GH treatment (Genotropin)) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant human growth hormone (somatropin). Area: Endocrinology.

marketed Recombinant human growth hormone (somatropin) Growth hormone receptor (GHR) Endocrinology Small molecule Live · refreshed every 30 min

Target snapshot

GH treatment (Genotropin) (GH treatment (Genotropin)) — Rabin Medical Center. Genotropin is recombinant human growth hormone (somatropin) that binds to growth hormone receptors to stimulate growth, metabolism, and body composition changes.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
GH treatment (Genotropin) TARGET GH treatment (Genotropin) Rabin Medical Center marketed Recombinant human growth hormone (somatropin) Growth hormone receptor (GHR)
CinnaTropin® CinnaTropin® Cinnagen phase 3 Recombinant human growth hormone (somatropin) Growth hormone receptor (GHR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant human growth hormone (somatropin) class)

  1. Cinnagen · 1 drug in this class
  2. Rabin Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). GH treatment (Genotropin) — Competitive Intelligence Brief. https://druglandscape.com/ci/gh-treatment-genotropin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: